Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2618 plus penpulimab in recurrent/metastatic nasopharyngeal carcinoma
CTR20240070Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2618 in nasopharyngeal carcinoma (NPC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jan 2024; status: terminated.
02
Drugs
TQB2618
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20240070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240070.